Bays HE, et al. - Researchers undertook this dose‐response study to determine the dose response of licogliflozin, a dual inhibitor of sodium/glucose cotransporter 1 (SGLT1) and 2 (SGLT2), by assessing alteration in body weight in adults having overweight or obesity. The participants were treated for 24 weeks with four once‐daily and twice‐daily licogliflozin doses (2.5‐150 mg) vs placebo (primary endpoint), and underwent evaluation for body weight change after that. Findings revealed significant reductions in body weight as a result of treatment with licogliflozin vs placebo, however, the magnitude of weight reduction was modest.